{"transactions":[{"id":746516,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and CDO"}}],"security":"Ordinary Shares","published_at":"2026-06-08T20:06:05.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of ordinary shares, par value $0.135 per share (\"ordinary shares\"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4)."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors."}],"balance_after":8789,"source":{"system":"sec-edgar","filing":"0001178913-26-003136","document":"zk2635517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003136/zk2635517.xml","form_type":"4"}},{"id":825413,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and CDO"}}],"security":"Ordinary Shares","published_at":"2026-03-30T21:29:47.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":22818,"price":1.36,"value":31032.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was a sale-to-cover to cover tax liability stemming from the Reporting Person's receipt of a grant of fully vested restricted share units on February 20, 2026, as reported in the Form 4 filed by the Reporting Person on February 23, 2026."}],"balance_after":27889,"source":{"system":"sec-edgar","filing":"0001178913-26-001858","document":"zk2634986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326001858/zk2634986.xml","form_type":"4"}},{"id":888359,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and CDO"}}],"security":"Ordinary Shares","published_at":"2026-02-23T21:18:24.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":49726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of ordinary shares, par value $0.0135 per share (\"ordinary shares\"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors."}],"balance_after":50707,"source":{"system":"sec-edgar","filing":"0001178913-26-000604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000604/ownership.xml","form_type":"4"}},{"id":4026378,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Innovation & Discovery"}}],"security":"Options","published_at":"2018-02-28T16:15:26.000Z","date":"2018-02-27","kind":"grant","acquired":true,"shares":15000,"price":6.4,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022."}],"balance_after":15000,"derivative":{"exercise_price":6.4,"expiration_date":"2028-02-27","underlying":"Ordinary Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001178913-18-000730","document":"zk1821311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000730/zk1821311.xml","form_type":"4"}},{"id":4026377,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Innovation & Discovery"}}],"security":"Ordinary Shares","published_at":"2018-02-28T16:15:26.000Z","date":"2018-02-27","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."}],"balance_after":24980,"source":{"system":"sec-edgar","filing":"0001178913-18-000730","document":"zk1821311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000730/zk1821311.xml","form_type":"4"}},{"id":4090756,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Innovation & Discovery"}}],"security":"Restricted Share Units","published_at":"2018-01-24T20:29:02.000Z","date":"2018-01-15","kind":"exercise","acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This class of restricted share units is included in Column 5 of Table I above."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001178913-18-000269","document":"a1821074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000269/a1821074.xml","form_type":"4"}},{"id":4090755,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Innovation & Discovery"}}],"security":"Restricted Share Units","published_at":"2018-01-24T20:29:02.000Z","date":"2018-01-01","kind":"exercise","acquired":false,"shares":2745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This class of restricted share units is included in Column 5 of Table I above."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":2745},"source":{"system":"sec-edgar","filing":"0001178913-18-000269","document":"a1821074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000269/a1821074.xml","form_type":"4"}},{"id":4090754,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Innovation & Discovery"}}],"security":"Ordinary Shares","published_at":"2018-01-24T20:29:02.000Z","date":"2018-01-15","kind":"exercise","acquired":true,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 2,745 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 10,489 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security."}],"balance_after":19980,"source":{"system":"sec-edgar","filing":"0001178913-18-000269","document":"a1821074.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000269/a1821074.xml","form_type":"4"}},{"id":4090753,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40578,"kind":"person","name":"Shirvan Mitchell","position":1,"cik":"0001727789","reported_name":"Shirvan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Innovation & Discovery"}}],"security":"Ordinary Shares","published_at":"2018-01-24T20:29:02.000Z","date":"2018-01-01","kind":"exercise","acquired":true,"shares":2745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 2,745 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 10,489 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security."}],"balance_after":19980,"source":{"system":"sec-edgar","filing":"0001178913-18-000269","document":"a1821074.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000269/a1821074.xml","form_type":"4"}}]}